Genomic drug developer Tessera Therapeutics raised $230m in a round co-led by SoftBank Vision Fund 2 as it works on its gene writing technology.
Telecommunications and internet conglomerate SoftBank’s Vision Fund 2 co-led a series B round for US-based genomic drug developer Tessera Therapeutics yesterday sized at more than $230m. The round was co-led by the state-owned Alaska Permanent Fund Corporation and venture capital firm Altitude Life Science Ventures, and it also featured sovereign wealth fund Qatar Investment Authority…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.